How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals

Structure

Volumn 27, Issue 2, 2019, Pages 211-217

  Westbrook, John D ^a   Burley, Stephen K ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biopharmaceutical industry; data deposition; drugs; FAIR principles; macromolecular crystallography; new molecular entities; open access; PDB; RCSB PDB; Research Collaboratory for Structural Bioinformatics Protein Databank; Worldwide PDB; wwPDB

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; GASTROINTESTINAL AGENT; IMMUNOLOGIC AGENT; NEW DRUG; RESPIRATORY TRACT AGENT; PROTEIN;

BIOLOGIST; CITATION ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; INVESTMENT; PRIORITY JOURNAL; PROTEIN DATA BANK; PUBLICATION; REVIEW; ANIMAL; BIBLIOMETRICS; CHEMISTRY; HUMAN; MOLECULAR MODEL; ORGANIZATION AND MANAGEMENT; PROTEIN CONFORMATION; PROTEIN DATABASE; STRUCTURE ACTIVITY RELATION; UNITED STATES;

ANIMALS; BIBLIOMETRICS; DATABASES, PROTEIN; DRUG APPROVAL; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85060712313     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2018.11.007     Document Type: Review

References (51)

1. Beierlein, J.M., McNamee, L.M., Walsh, M.J., Kaitin, K.I., DiMasi, J.A., Ledley, F.D., Landscape of innovation for cardiovascular pharmaceuticals: from basic science to new molecular entities. Clin. Ther. 39 (2017), 1409–1425.e20.
2. Berman, H.M., Henrick, K., Nakamura, H., Announcing the Worldwide Protein Data Bank. Nat. Struct. Biol., 10, 2003, 980.
3. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The Protein Data Bank. Nucleic Acids Res. 28 (2000), 235–242.
4. Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strominger, J.L., Wiley, D.C., Structure of the human class I histocompatibility antigen, HLA-A2. Nature, 329, 1987, 506.
5. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B., Rerat, C., Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J. Mol. Biol. 121 (1978), 339–356.
6. Blundell, T.L., Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry. IUCr J. 4 (2017), 308–321.
7. Blundell, T.L., Cutfield, J.F., Cutfield, S.M., Dodson, E.J., Dodson, G.G., Hodgkin, D.C., Mercola, D.A., Vijayan, M., Atomic positions in rhombohedral 2-zinc insulin crystals. Nature 231 (1971), 506–511.
8. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 (2010), 596–599.
9. Burley, S.K., Berman, H.M., Christie, C., Duarte, J., Feng, Z., Westbrook, J., Young, J., Zardecki, C., RCSB Protein Data Bank: sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education. Protein Sci. 27 (2018), 316–330.
10. Burley, S.K., Joachimiak, A., Montelione, G.T., Wilson, I.A., Contributions to the NIH-NIGMS protein structure initiative from the PSI production centers. Structure 16 (2008), 5–11.
11. Capdeville, R., Buchdunger, E., Zimmermann, J., Matter, A., Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1 (2002), 493–502.
12. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W. Jr., Leahy, D.J., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003), 756–760.
13. DiMasi, J.A., Grabowski, H.G., Hansen, R.W., Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47 (2016), 20–33.
14. Dvir, H., Harel, M., McCarthy, A.A., Toker, L., Silman, I., Futerman, A.H., Sussman, J.L., X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4 (2003), 704–709.
15. Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., de Vos, A.M., Sliwkowski, M.X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004), 317–328.
16. Galkina Cleary, E., Beierlein, J.M., Khanuja, N.S., McNamee, L.M., Ledley, F.D., Contribution of NIH funding to new drug approvals 2010-2016. Proc. Natl. Acad. Sci. U S A 115 (2018), 2329–2334.
17. Gathiaka, S., Liu, S., Chiu, M., Yang, H., Stuckey, J.A., Kang, Y.N., Delproposto, J., Kubish, G., Dunbar, J.B. Jr., Carlson, H.A., et al. D3R grand challenge 2015: evaluation of protein-ligand pose and affinity predictions. J. Comput. Aided Mol. Des. 30 (2016), 651–668.
18. Gilliland, G.L., Luo, J., Vafa, O., Almagro, J.C., Leveraging SBDD in protein therapeutic development: antibody engineering. Methods Mol. Biol. 841 (2012), 321–349.
19. Gilmer, T., Rodriguez, M., Jordan, S., Crosby, R., Alligood, K., Green, M., Kimery, M., Wagner, C., Kinder, D., Charifson, P., et al. Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 269 (1994), 31711–31719.
20. Gore, S., Sanz Garcia, E., Hendrickx, P.M.S., Gutmanas, A., Westbrook, J.D., Yang, H., Feng, Z., Baskaran, K., Berrisford, J.M., Hudson, B.P., et al. Validation of the structures in the Protein Data Bank. Structure 25 (2017), 1916–1927.
21. Hu, T., Sprague, E.R., Fodor, M., Stams, T., Clark, K.L., Cowan-Jacob, S.W., The impact of structural biology in medicine illustrated with four case studies. J. Mol. Med. (Berl.) 96 (2018), 9–19.
22. Kane, S.P., ClinCalc DrugStats Database Version 19.0. 2018, ClinCalc LLC.
23. Kinjo, A.R., Bekker, G.J., Suzuki, H., Tsuchiya, Y., Kawabata, T., Ikegawa, Y., Nakamura, H., Protein Data Bank Japan (PDBj): updated user interfaces, resource description framework, analysis tools for large structures. Nucleic Acids Res. 45 (2017), D282–D288.
24. Klebe, G., Drug Design - Methodology, Concepts, and Mode-of-action. 2013, Springer.
25. Lazar-Molnar, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S.G., Almo, S.C., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl. Acad. Sci. U S A 105 (2008), 10483–10488.
26. Lee, J.Y., Lee, H.T., Shin, W., Chae, J., Choi, J., Kim, S.H., Lim, H., Won Heo, T., Park, K.Y., Lee, Y.J., et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Commun., 7, 2016, 13354.
27. Lin, D.Y., Tanaka, Y., Iwasaki, M., Gittis, A.G., Su, H.P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., Garboczi, D.N., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. U S A 105 (2008), 3011–3016.
28. Moffat, J.G., Vincent, F., Lee, J.A., Eder, J., Prunotto, M., Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16 (2017), 531–543.
29. Mullard, A., 2015 FDA drug approvals. Nat. Rev. Drug Discov. 15 (2016), 73–76.
30. Na, Z., Yeo, S.P., Bharath, S.R., Bowler, M.W., Balikci, E., Wang, C.I., Song, H., Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 27 (2017), 147–150.
31. Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B., Kuriyan, J., Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002), 4236–4243.
32. Nar, H., The role of structural information in the discovery of direct thrombin and factor Xa inhibitors. Trends Pharm. Sci. 33 (2012), 279–288.
33. Norwood, F.L., Sutherland-Smith, A.J., Keep, N.H., Kendrick-Jones, J., The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure 8 (2000), 481–491.
34. Olson, E.M., Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. J. Clin. Oncol. 30 (2012), 1712–1714.
35. Penchala, S.C., Connelly, S., Wang, Y., Park, M.S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R.M., et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. U S A 110 (2013), 9992–9997.
36. Pioszak, A.A., Xu, H.E., Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl. Acad. Sci. U S A 105 (2008), 5034–5039.
37. Protein Data Bank. Crystallography: Protein Data Bank. Nat. New Biol., 233, 1971, 223.
38. Renaud, J.-P., Chari, A., Ciferri, C., Liu, W.-t., Rémigy, H.-W., Stark, H., Wiesmann, C., Cryo-EM in drug discovery: achievements, limitations and prospects. Nat. Rev. Drug Discov. 17 (2018), 471–492.
39. Scapin, G., Yang, X., Prosise, W.W., McCoy, M., Reichert, P., Johnston, J.M., Kashi, R.S., Strickland, C., Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat. Struct. Mol. Biol. 22 (2015), 953–958.
40. Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., Litzenburger, T., A specific antidote for dabigatran: functional and structural characterization. Blood 121 (2013), 3554–3562.
41. Steensgaard, D.B., Schluckebier, G., Strauss, H.M., Norrman, M., Thomsen, J.K., Friderichsen, A.V., Havelund, S., Jonassen, I., Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry 52 (2013), 295–309.
42. Stoll, F., Goller, A.H., Hillisch, A., Utility of protein structures in overcoming ADMET-related issues of drug-like compounds. Drug Discov. Today 16 (2011), 530–538.
43. Tripsianes, K., Madl, T., Machyna, M., Fessas, D., Englbrecht, C., Fischer, U., Neugebauer, K.M., Sattler, M., Structural basis for dimethylarginine recognition by the Tudor domains of human SMN and SPF30 proteins. Nat. Struct. Mol. Biol. 18 (2011), 1414–1420.
44. Ulrich, E.L., Akutsu, H., Doreleijers, J.F., Harano, Y., Ioannidis, Y.E., Lin, J., Livny, M., Mading, S., Maziuk, D., Miller, Z., et al. BioMagResBank. Nucleic Acids Res. 36 (2008), D402–D408.
45. Velankar, S., Best, C., Beuth, B., Boutselakis, C.H., Cobley, N., Sousa Da Silva, A.W., Dimitropoulos, D., Golovin, A., Hirshberg, M., John, M., et al. PDBe: Protein Data Bank in Europe. Nucleic Acids Res. 38 (2010), D308–D317.
46. Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.W., da Silva Santos, L.B., Bourne, P.E., et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data, 3, 2016, 160018.
47. Wlodawer, A., Vondrasek, J., Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998), 249–284.
48. Young, J.Y., Westbrook, J.D., Feng, Z., Peisach, E., Persikova, I., Sala, R., Sen, S., Berrisford, J.M., Swaminathan, G.J., Oldfield, T.J., et al. Worldwide Protein Data Bank biocuration supporting open access to high-quality 3D structural biology data. Database (Oxford), 2018, 2018, 10.1093/database/bay002.
49. Young, J.Y., Westbrook, J.D., Feng, Z., Sala, R., Peisach, E., Oldfield, T.J., Sen, S., Gutmanas, A., Armstrong, D.R., Berrisford, J.M., et al. OneDep: unified wwPDB system for deposition, biocuration, and validation of macromolecular structures in the PDB archive. Structure 25 (2017), 536–545.
50. Zhang, F., Basinski, M.B., Beals, J.M., Briggs, S.L., Churgay, L.M., Clawson, D.K., DiMarchi, R.D., Furman, T.C., Hale, J.E., Hsiung, H.M., et al. Crystal structure of the obese protein leptin-E100. Nature 387 (1997), 206–209.
51. Zhang, X., Schwartz, J.C., Guo, X., Bhatia, S., Cao, E., Lorenz, M., Cammer, M., Chen, L., Zhang, Z.Y., Edidin, M.A., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20 (2004), 337–347.